State-based Reform
-
340B, Alzheimer’s, Caught my eye, Drug Prices, Drug shortages, Medicare Advantage, State-based ReformCaught my eye — 1/26/24
Read more: Caught my eye — 1/26/24It has been fun to see the year really start to kick off this week with a bunch of policy releases. Shortages. Generic shortages are caused by a myriad of factors, but a big piece is the race to the bottom for prices. A fraction of a penny less and a contract shifts to another…
-
Another bite at the apple
Read more: Another bite at the appleIt used to be that pharmaceutical manufacturers had to worry (mostly) about federal health policy. Every few years manage through a big piece of legislation from Congress and then the regulation on Medicare, Medicaid, the Affordable Care Act and any regulation that came out of the legislation. But over the past few years, the drug…
Latest news
- AMP is WAC — 04/24/26
- AMP is WAC — 04/10/26
- AMP is WAC — 03/27/26
- AMP is WAC — 03/20/26
- AMP is WAC — 03/13/26
Categories
- 340B (64)
- Affordable Care Act (23)
- Alzheimer's (11)
- Biosimilars (33)
- Caught my eye (102)
- Cell and Gene (8)
- Chevron Deference (2)
- CMMI (29)
- Copay Accumulators (7)
- COVID (3)
- Drug Prices (58)
- Drug shortages (15)
- DTC (9)
- Employers (20)
- FDA (8)
- Generics (13)
- Health Equity (4)
- Healthcare Costs (41)
- Home Health (1)
- ICER (12)
- Importation (5)
- Inflation Reduction Act (69)
- Insulin (7)
- IP (3)
- Long term care (1)
- Medicaid (24)
- Medicare Advantage (27)
- Medicare Negotiation (68)
- Medicare Part D (78)
- Medicare Transaction Facilitator (5)
- Medicare Transaction Facilitator (12)
- Obesity (28)
- On the Horizon (1)
- Orphan Drugs (8)
- Pharmacy Benefit Managers (49)
- Preventative (5)
- Reference Pricing (26)
- State-based Reform (32)
- Supply Chain (8)
- Tariffs (2)
- Uncategorized (9)
- Utilization Management (14)
- Vaccines (10)
- Value (18)